Vor Bio soars as initial data from blood cancer study shows promise

Vor Biopharma

07/12/2022 16:15

(Updates)
    ** Shares of Vor Bio  VOR.O  jump 29.5% to $5.57, among the
top pct gainers across the U.S. stock exchanges
        ** Stock posts biggest one-day pct gain since its IPO
debut in Feb 2021
    ** The drug developer says initial data from
early-to-mid-stage study of its experimental therapy to treat
patients with a type of blood cancer was well-tolerated
 urn:newsml:reuters.com:*:nGNX2tP23x
    ** Blood count was successfully maintained in the first
patient after the transplant treatment - VOR 
    ** Co says the study continues to enroll patients and
additional data is expected in 2023
    ** Including session gains, stock down ~52% YTD 
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))